2023 ASCO中国之声｜胃食管与肝胆胰肿瘤领域壁报部分共37项中国研究入选！

一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。

随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国胃食管与肝胆胰肿瘤领域Poster Session共入选37项。期待中国专家在ASCO年会上展现风采！

标题：A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

报告人：黄镜

单位：中国医学科学院肿瘤医院

标题：A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data.

报告人：季加孚

单位：北京大学肿瘤医院

标题：EpCAM CAR T (IMC001) for the treatment of advanced GI cancers.

报告人：Guoqiang Ai

单位：Suzhou Immunofoco Biotechnology Co., Ltd

标题：Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.

报告人：Xiaoting Ma

单位：中国医学科学院肿瘤医院

标题：Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.

报告人：Zhiye Zhang

单位：河南科技大学第一附属医院

标题：Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

报告人：沈琳

单位：北京大学肿瘤医院

标题：Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).

报告人：Guangyu Yao

单位：复旦大学附属中山医院

标题：Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.

报告人：弓磊

单位：天津医科大学肿瘤医院

标题：Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).

报告人：鲁智豪

单位：北京大学肿瘤医院

标题：Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.

报告人：俞鹏飞

单位：浙江省肿瘤医院

标题：Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).

报告人：陈宝清

单位：中山大学肿瘤防治中心

标题：Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma.

报告人：Lizhen Wang

单位：罗氏(中国)投资有限公司

标题：Multi-dimensional cell-free DNA-based liquid biopsy and early detection of gastric cancer.

报告人：俞鹏飞

单位：浙江省肿瘤医院

标题：Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial.

报告人：习勉

单位：中山大学肿瘤防治中心

标题：Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.

报告人：张仁泉

单位：安徽医科大学第一附属医院

标题：Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.

报告人：Peng Jin

单位：山东省肿瘤医院

标题：GaEsSeer: Early detection of gastric and esophageal cancer by integrating methylation and fragmentomics signatures in cfDNA.

报告人：钟芸诗

单位：复旦大学附属中山医院

标题：Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.

报告人：何文卓

单位：中山大学肿瘤防治中心

标题：Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

报告人：张志波

单位：福建医科大学附属第一医院

标题：An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

报告人：毕锋

单位：四川大学华西医院

标题：Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

报告人：李金鹏

单位：山东第一医科大学

标题：Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.

报告人：袁振刚

单位：上海东方肝胆外科医院

标题：Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.

报告人：Yi Zheng

单位：浙江大学医学院附属第一医院

标题：A prospective, open-label, randomized, controlled trial of radiofrequency ablation versus stereotactic body radiation therapy for recurrent small hepatocellular carcinoma.

报告人：张耀军

单位：中山大学肿瘤防治中心

标题：Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.

报告人：Zijie Zhang

单位：上海交通大学医学院附属仁济医院

标题：Adjuvant immune checkpoint inhibitors and association with recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective cohort study.

报告人：Le Li

单位：广西医科大学附属肿瘤医院

标题：Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.

报告人：崔云龙

单位：天津医科大学肿瘤医院

标题：Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.

报告人：Baojiang Liu

单位：北京大学肿瘤医院

标题：Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.

报告人：Chi Leung Chiang

单位：香港大学

标题：A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.

报告人：周俭

单位：复旦大学附属中山医院

标题：Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.

报告人：Rui Liu

单位：江苏鹍远生物技术有限公司

标题：The efficacy of radical hepatectomy versus stereotactic body radiotherapy for primary hepatocellular carcinoma: A propensity score matching analysis.

报告人：Yulin Hu

单位：深圳大学

标题：A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).

报告人：Haiyan Si

单位：中国人民解放军总医院第五医学中心

标题：PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with borderline resectable and locally advanced pancreatic cancer: A biomolecular exploratory, single-arm phase II clinical trial.

报告人：杜娟

单位：南京大学医学院附属鼓楼医院

标题：Detection and localization of gastrointestinal cancers based on multi-dimentional signatures from a single cfDNA targeted sequencing assay.

报告人：杨欣荣

单位：复旦大学附属中山医院

标题：NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.

报告人：Xiaodong Wang

单位：北京大学肿瘤医院